Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Authors
Keywords
-
Journal
JAMA Oncology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2022-10-27
DOI
10.1001/jamaoncol.2022.5041
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TNF in the era of immune checkpoint inhibitors: friend or foe?
- (2021) Allen Y. Chen et al. Nature Reviews Rheumatology
- Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy
- (2021) Xue Bai et al. CLINICAL CANCER RESEARCH
- TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out
- (2021) Karijn P. M. Suijkerbuijk et al. Nature Reviews Rheumatology
- Reply to: TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out
- (2021) Anne R. Bass et al. Nature Reviews Rheumatology
- Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment
- (2021) Ying Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry
- (2020) Rik J. Verheijden et al. CLINICAL CANCER RESEARCH
- TNF-alpha Blockade in Checkpoint Inhibition: The Good, the Bad or the Ugly?
- (2020) Jeffrey S. Weber et al. CLINICAL CANCER RESEARCH
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- (2020) Alexander M. M. Eggermont et al. JAMA Oncology
- Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2020) Fausto Petrelli et al. Cancers
- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
- (2020) Xiaoxiang Zhou et al. BMC Medicine
- Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study
- (2020) Michiel C.T. van Zeijl et al. JOURNAL OF IMMUNOTHERAPY
- Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma
- (2019) Candice Lesage et al. JOURNAL OF IMMUNOTHERAPY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
- (2018) Yinghong Wang et al. Journal for ImmunoTherapy of Cancer
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
- (2018) Daniel H Johnson et al. Journal for ImmunoTherapy of Cancer
- Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands
- (2017) Anouk Jochems et al. EUROPEAN JOURNAL OF CANCER
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now